Head Neck Cancer
Conditions
Keywords
Electrochemotherapy, head neck cancer, bleomycin
Brief summary
A phase II clinical trial testing electrochemotherapy on mucosal recurrent head and neck cancer. Twenty-five patients will be treated. Primary outcome is tumour response on imaging. Secondary outcomes are response from tissue samples, VAS score, Quality of life evaluation and side effects to treatment.
Detailed description
Electric pulses may be used to transiently permeabilise cell membranes, enabling passage of otherwise non-permeating molecules. This dramatically enhances the cytotoxic effect of certain chemotherapeutic agents, and is termed electrochemotherapy. Electrochemotherapy is now standardly used in the treatment of cutaneous metastases of various cancers in over 100 cancer centers around Europe. The intention of this trial is to investigate the possible use of electrochemotherapy in recurrent head and neck cancer as a palliative treatment. Surgery and radiotherapy, with the possible addition of chemotherapy, cures a large part of patients with head and neck cancer. However, in the event of recurrence curative options may be exhausted and the patient is referred for palliative chemotherapy. It is for this patient group, the investigators propose electrochemotherapy in a clinical trial. The electrochemotherapy is administered as a once-only treatment, with possible retreatment after eight weeks. Under general anesthesia, chemotherapy is administered intravenously, followed by application of electric pulses to the tumour area. Before treatment, the location and spread of the tumour is determined by imaging. The trial includes evaluation of response by MRI (magnetic resonance imaging) and PET/CT (Positron Emission Tomography - Computed Tomography) scans (base-line, 4 weeks, 8 weeks), tissue samples, as well as adverse events registration and questionnaires on quality of life. The planned study is a phase II clinical study, prospective, observational with up to 25 patients. Treatments will be performed in collaboration between the Department of Oncology, Copenhagen University Hospital Herlev, which has extensive experience in electrochemotherapy, and the Department of Ear Nose and Throat Surgery at Copenhagen University Hospital Rigshospitalet, that has the surgical expertise and set-up needed.
Interventions
PROCEDUREElectrochemotherapy
Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
DEVICECliniporator
Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
DRUGBleomycin
Administered intravenously or injected into the tumour before electroporation.
Sponsors
Copenhagen University Hospital at Herlev
Rigshospitalet, Denmark
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subject age \> 18 years. 2. Verified cancer of the head and neck area of any histology. 3. At least one tumour lesion should be accessible for electroporation. 4. Performance status WHO \<= 2nd 5. Progressive and / or metastatic disease. 6. Expected survival of \> 3 months. 7. Measurable disease is defined as at least one measurable lesion by RECIST 1.1. 8. A treatment-free interval of more than 4 weeks since chemotherapy or radiation therapy. 9. The participant should have been offered the current standard treatment. If there are no further standard treatment to offer or if the participant does not want to receive this, the participant may be included in the trial. 10. The participant should be able to understand the information for participants and be willing and able to comply with hospitalization in the treatment and the agreed follow-up visits and tests. 11. Platelets ≥ 50 billion / L, INR (international normalized ratio) \> 1.5. Medical correction is permitted, e.g. correction using vitamin K. 12. Sexually active women who can become pregnant should use adequate contraception during this trial and 6 months after administration of bleomycin (pill, spiral, injection of prolonged progestin subdermal implantation, hormone-containing vaginal devices, transdermal patches). 13. Signed informed consent. -
Exclusion criteria
Participants should be excluded if they meet just one of the criteria stated below. 1. Symptomatic progression of the participants cancerous disease that requires another intervention. 2. Acute lung infection 3. Symptoms of lung function impairment. This triggers a lung function test (DLCO = diffusing capacity of the lungs for carbon monoxide), if moderate to severe the participant will be excluded. 4. Previous bleomycin treatment with cumulative dose more than 240,000 Units / m2. 5. History of severe allergic reactions associated with bleomycin. 6. Allergy to constituents of the planned anesthetic. 7. Coagulation disorder which can not be corrected. 8. Chronic renal dysfunction with creatinine\> 150 micromoles / liter, will trigger a Cr-51-EDTA (Chromium-51-ethylenediamine tetra acetic acid) clearance. If this is too impaired, the participant is excluded. 9. Pregnancy or lactation. 10. While participation in other clinical trials involving experimental drugs or involved in a trial within 4 weeks prior to study drug administration. 11. Other disorders investigator finds incompatible with participation in the trial. -
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumour response from PET/CT scans (Positron Emission Tomography - Computed Tomography) | 8 weeks after treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| VAS score (Visual Analogue Scale) | baseline, 4 weeks and 8 weeks after treatment | Participant assessed |
| Tumour response from MRI scans (Magnetic resonance imaging) | 8 weeks after treatment | — |
| Tumour response from tissue samples | 4 weeks after treatment | Still cancer activity or not |
| Quality of life | baseline, 4 weeks and 8 weeks after treatment | EORTC scores for head and neck (The European Organisation for Research and Treatment of Cancer) |
| CTCAE recordings (Common Terminology Criteria for Adverse Events) | baseline, 4 weeks and 8 weeks after treatment | side effects scored by CTCAE version 4.0 |
Countries
Denmark
Contacts
Primary ContactChristina C. Plaschke, MD
Backup ContactIrene Wessel, MD
Outcome results
None listed